NCT05161702

Brief Summary

The purpose of this biological study is to provide Dr. Samuel Fortin's laboratory with a continuous supply of blood mononuclear cells (PBMCs) so that he can pursue research on the potential beneficial effects of monoglyceride omega-3 fatty acids on the resolution of inflammation.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
8mo left

Started Mar 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress92%
Mar 2019Jan 2027

Study Start

First participant enrolled

March 12, 2019

Completed
2.8 years until next milestone

First Submitted

Initial submission to the registry

December 15, 2021

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 17, 2021

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2027

Last Updated

April 17, 2026

Status Verified

April 1, 2026

Enrollment Period

7.8 years

First QC Date

December 15, 2021

Last Update Submit

April 16, 2026

Conditions

Resolution of InflammationReduction of Cell Proliferation

Outcome Measures

Primary Outcomes (1)

  • Number of PBMC cells count

    12 months

Interventions

MAG-SPM treatment on isolated PBMC cellsOTHER

Cells are isolated form the participant's blood donation (4x 10mL k2EDTA tubes per participant) and maintained in culture with LPS, a pro-inflammatory and pro-proliferative agent. Then, PBMC are separated in two, one half treated with MAG-SPM and the other half remains with LPS only. Proliferative activities are measured and compared in both cell dish.

Isolated PBMC cells without treatment.OTHER

Cells are isolated form the participant's blood donation (4x 10mL k2EDTA tubes per participant) and maintained in culture with LPS, a pro-inflammatory and pro-proliferative agent. Then, PBMC are separated in two, one half treated with MAG-SPM and the other half remains with LPS only. Proliferative activities are measured and compared in both cell dish.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Healthy adult blood donors

You may qualify if:

  • Participant aged of at least 18 years old.

You may not qualify if:

  • Participant who use omega-3 supplements and / or anti-inflammatory medication such as, but not limited to - Aspirin, Ibuprofen (Motrin, Advil), Celecoxib (Celebrex), diclofenac (Cambia, Cataflam, Voltaren ) within 7 days of day 1 of the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

SCF Pharma

Rimouski, Quebec, G0K 1P0, Canada

RECRUITING

MeSH Terms

Interventions

Therapeutics

Study Officials

  • Samuel P Fortin, PhD

    SCF Pharma

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Samuel Fortin, PhD

CONTACT

418-750-8590sfortin@scfpharma.com

Anne-Julie Landry, M.Sc

CONTACT

ajlandry@scfpharma.com

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
OTHER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 15, 2021

First Posted

December 17, 2021

Study Start

March 12, 2019

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

January 1, 2027

Last Updated

April 17, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations

CA(1)